Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 271 articles:
HTML format
Text format



Single Articles


    February 2019
  1. WOODHEAD C, Cunningham R, Ashworth M, Barley E, et al
    Correction to: Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study.
    BMC Cancer. 2019;19:152.
    PubMed     Text format     Abstract available


  2. PETITJEAN A, Smith-Palmer J, Valentine W, Tehard B, et al
    Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
    BMC Cancer. 2019;19:140.
    PubMed     Text format     Abstract available


  3. WANG L, Liu L, Lou Z, Ding L, et al
    Risk prediction for breast Cancer in Han Chinese women based on a cause-specific Hazard model.
    BMC Cancer. 2019;19:128.
    PubMed     Text format     Abstract available


  4. KAHAN Z, Grecea D, Smakal M, Tjulandin S, et al
    Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    BMC Cancer. 2019;19:122.
    PubMed     Text format     Abstract available


  5. KONIG L, Mairinger FD, Hoffmann O, Bittner AK, et al
    Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.
    BMC Cancer. 2019;19:120.
    PubMed     Text format     Abstract available


  6. GALLARDO-ALVARADO LN, Tusie-Luna MT, Tussie-Luna MI, Diaz-Chavez J, et al
    Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
    BMC Cancer. 2019;19:118.
    PubMed     Text format     Abstract available


    January 2019
  7. DARLIX A, Hirtz C, Thezenas S, Maceski A, et al
    The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
    BMC Cancer. 2019;19:110.
    PubMed     Text format     Abstract available


  8. SCHAFFAR R, Belot A, Rachet B, Woods L, et al
    On the use of flexible excess hazard regression models for describing long-term breast cancer survival: a case-study using population-based cancer registry data.
    BMC Cancer. 2019;19:107.
    PubMed     Text format     Abstract available


  9. MUMIN NH, Drobnitzky N, Patel A, Lourenco LM, et al
    Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    BMC Cancer. 2019;19:102.
    PubMed     Text format     Abstract available


  10. ZHAO ZM, Yost SE, Hutchinson KE, Li SM, et al
    CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
    BMC Cancer. 2019;19:96.
    PubMed     Text format     Abstract available


  11. KOTSAKIS A, Ardavanis A, Koumakis G, Samantas E, et al
    Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
    BMC Cancer. 2019;19:88.
    PubMed     Text format     Abstract available


  12. EBNER F, Wockel A, Schwentner L, Blettner M, et al
    Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival?
    BMC Cancer. 2019;19:90.
    PubMed     Text format     Abstract available


  13. KIM HK, Lee SH, Kim YJ, Park SE, et al
    Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
    BMC Cancer. 2019;19:84.
    PubMed     Text format     Abstract available


  14. MIAH S, Bagu E, Goel R, Ogunbolude Y, et al
    Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.
    BMC Cancer. 2019;19:78.
    PubMed     Text format     Abstract available


  15. JEVRIC M, Matic IZ, Krivokuca A, Dordic Crnogorac M, et al
    Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
    BMC Cancer. 2019;19:71.
    PubMed     Text format     Abstract available


  16. KIRKHAM AA, Ian Paterson D, Prado CM, Mackey JR, et al
    Correction to: Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    BMC Cancer. 2019;19:75.
    PubMed     Text format     Abstract available


  17. KHODABANDEHLOU N, Mostafaei S, Etemadi A, Ghasemi A, et al
    Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins.
    BMC Cancer. 2019;19:61.
    PubMed     Text format     Abstract available


  18. BORGQUIST S, Broberg P, Tojjar J, Olsson H, et al
    Statin use and breast cancer survival - a Swedish nationwide study.
    BMC Cancer. 2019;19:54.
    PubMed     Text format     Abstract available


  19. LOFTERS AK, McBride ML, Li D, Whitehead M, et al
    Disparities in breast cancer diagnosis for immigrant women in Ontario and BC: results from the CanIMPACT study.
    BMC Cancer. 2019;19:42.
    PubMed     Text format     Abstract available


  20. FRAMARINO-DEI-MALATESTA M, Chiarito A, Bianciardi F, Fiorelli M, et al
    Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature.
    BMC Cancer. 2019;19:36.
    PubMed     Text format     Abstract available


  21. MECHERA R, Soysal SD, Piscuoglio S, Ng CKY, et al
    Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.
    BMC Cancer. 2019;19:41.
    PubMed     Text format     Abstract available


  22. SUN J, Wang X, Wang C
    Invasive cystic hypersecretory carcinoma of the breast: a rare variant of breast cancer: a case report and review of the literature.
    BMC Cancer. 2019;19:31.
    PubMed     Text format     Abstract available


  23. MASELLI-SCHOUERI JH, Affonso-Kaufman FA, de Melo Sette CV, Dos Santos Figueiredo FW, et al
    Time trend of breast cancer mortality in BRAZILIAN men: 10-year data analysis from 2005 to 2015.
    BMC Cancer. 2019;19:23.
    PubMed     Text format     Abstract available


  24. DE KRUIF JTCM, Visser M, van den Berg MMGA, Derks MJM, et al
    A longitudinal mixed methods study on changes in body weight, body composition, and lifestyle in breast cancer patients during chemotherapy and in a comparison group of women without cancer: study protocol.
    BMC Cancer. 2019;19:7.
    PubMed     Text format     Abstract available


    December 2018
  25. HAMDI Y, Ben Rekaya M, Jingxuan S, Nagara M, et al
    A genome wide SNP genotyping study in the Tunisian population: specific reporting on a subset of common breast cancer risk loci.
    BMC Cancer. 2018;18:1295.
    PubMed     Text format     Abstract available


  26. ZHAO J, Hu C, Wang C, Yu W, et al
    Breast cancer primary tumor ER expression pattern predicts its expression concordance in matched synchronous lymph node metastases.
    BMC Cancer. 2018;18:1290.
    PubMed     Text format     Abstract available


  27. TAKUWA H, Tsuji W, Shintaku M, Yotsumoto F, et al
    Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report.
    BMC Cancer. 2018;18:1282.
    PubMed     Text format     Abstract available


  28. KUEHNEMUTH B, Piseddu I, Wiedemann GM, Lauseker M, et al
    CCL1 is a major regulatory T cell attracting factor in human breast cancer.
    BMC Cancer. 2018;18:1278.
    PubMed     Text format     Abstract available


  29. SCHMID R, Wolf K, Robering JW, Strauss S, et al
    ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro.
    BMC Cancer. 2018;18:1273.
    PubMed     Text format     Abstract available


  30. FORSARE C, Bak M, Falck AK, Grabau D, et al
    Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer.
    BMC Cancer. 2018;18:1226.
    PubMed     Text format     Abstract available


  31. MOHAMMAD AS, Adkins CE, Shah N, Aljammal R, et al
    Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer.
    BMC Cancer. 2018;18:1225.
    PubMed     Text format     Abstract available


  32. FARIAS AJ, Wu WH, Du XL
    Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
    BMC Cancer. 2018;18:1214.
    PubMed     Text format     Abstract available


  33. LI TY, Chen VC, Yeh DC, Huang SL, et al
    Investigation of chemotherapy-induced brain structural alterations in breast cancer patients with generalized q-sampling MRI and graph theoretical analysis.
    BMC Cancer. 2018;18:1211.
    PubMed     Text format     Abstract available


    November 2018
  34. CIFU G, Power MC, Shomstein S, Arem H, et al
    Mindfulness-based interventions and cognitive function among breast cancer survivors: a systematic review.
    BMC Cancer. 2018;18:1163.
    PubMed     Text format     Abstract available


  35. VAN OMMEN-NIJHOF A, Konings IR, van Zeijl CJJ, Uyl-de Groot CA, et al
    Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    BMC Cancer. 2018;18:1146.
    PubMed     Text format     Abstract available


  36. JIN B, Zhang S, Chuang X, Yu P, et al
    Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report.
    BMC Cancer. 2018;18:1138.
    PubMed     Text format     Abstract available


  37. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer.
    BMC Cancer. 2018;18:1137.
    PubMed     Text format     Abstract available


  38. JEONG J, Seo K, Kim ES
    Numerical analysis of intracellular amino acid profiles of breast cancer cells with K-Ras or PI3K mutation in response to kinase inhibitors.
    BMC Cancer. 2018;18:1109.
    PubMed     Text format     Abstract available


  39. OBERSTE M, Schaffrath N, Schmidt K, Bloch W, et al
    Protocol for the "Chemobrain in Motion - study" (CIM - study): a randomized placebo-controlled trial of the impact of a high-intensity interval endurance training on cancer related cognitive impairments in women with breast cancer receiving first-line
    BMC Cancer. 2018;18:1071.
    PubMed     Text format     Abstract available


  40. RINNERTHALER G, Gampenrieder SP, Petzer A, Burgstaller S, et al
    Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
    BMC Cancer. 2018;18:1074.
    PubMed     Text format     Abstract available


    October 2018
  41. GASS P, Lux MP, Rauh C, Hein A, et al
    Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
    BMC Cancer. 2018;18:1051.
    PubMed     Text format     Abstract available


  42. LUHTALA S, Staff S, Kallioniemi A, Tanner M, et al
    Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    BMC Cancer. 2018;18:1045.
    PubMed     Text format     Abstract available


  43. CHEN L, Qi H, Zhang L, Li H, et al
    Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients.
    BMC Cancer. 2018;18:1038.
    PubMed     Text format     Abstract available


  44. ARCINIEGAS CALLE MC, Sandhu NP, Xia H, Cha SS, et al
    Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    BMC Cancer. 2018;18:1037.
    PubMed     Text format     Abstract available


  45. JOHNSTON SJ, Ahmad D, Aleskandarany MA, Kurozumi S, et al
    Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.
    BMC Cancer. 2018;18:1027.
    PubMed     Text format     Abstract available


  46. VARGA K, Hollosi A, Paszty K, Hegedus L, et al
    Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.
    BMC Cancer. 2018;18:1029.
    PubMed     Text format     Abstract available


  47. SARINK D, Schock H, Johnson T, Chang-Claude J, et al
    Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
    BMC Cancer. 2018;18:1010.
    PubMed     Text format     Abstract available


  48. SMITH YE, Toomey S, Napoletano S, Kirwan G, et al
    Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
    BMC Cancer. 2018;18:1016.
    PubMed     Text format     Abstract available


  49. DALMASSO B, Hatse S, Brouwers B, Laenen A, et al
    Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy.
    BMC Cancer. 2018;18:1014.
    PubMed     Text format     Abstract available


  50. ZHAO Y, Lv F, Chen S, Wang Z, et al
    Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
    BMC Cancer. 2018;18:1019.
    PubMed     Text format     Abstract available


  51. YANG Y, Cameron J, Bedi C, Humphris G, et al
    Fear of cancer recurrence trajectory during radiation treatment and follow-up into survivorship of patients with breast cancer.
    BMC Cancer. 2018;18:1002.
    PubMed     Text format     Abstract available


  52. GEERS J, Wildiers H, Van Calster K, Laenen A, et al
    Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer.
    BMC Cancer. 2018;18:994.
    PubMed     Text format     Abstract available


  53. REN JT, Wang MX, Su Y, Tang LY, et al
    Decelerated DNA methylation age predicts poor prognosis of breast cancer.
    BMC Cancer. 2018;18:989.
    PubMed     Text format     Abstract available


  54. ARAKI K, Ito Y, Fukada I, Kobayashi K, et al
    Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
    BMC Cancer. 2018;18:982.
    PubMed     Text format     Abstract available


  55. DA SILVA BB, Eulalio Filho WMN, Costa PVL, Silva RA, et al
    A rare case of primary breast angiosarcoma in a male: a case report.
    BMC Cancer. 2018;18:978.
    PubMed     Text format     Abstract available


  56. LI L, Chang B, Jiang X, Fan X, et al
    Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
    BMC Cancer. 2018;18:977.
    PubMed     Text format     Abstract available


  57. EUSTACE AJ, Conlon NT, McDermott MSJ, Browne BC, et al
    Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
    BMC Cancer. 2018;18:965.
    PubMed     Text format     Abstract available


  58. GHOREISHI Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, et al
    Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
    BMC Cancer. 2018;18:958.
    PubMed     Text format     Abstract available


  59. LEE KH, Kim EY, Yun JS, Park YL, et al
    The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer.
    BMC Cancer. 2018;18:938.
    PubMed     Text format     Abstract available


    September 2018
  60. INVERNIZZI M, Corti C, Lopez G, Michelotti A, et al
    Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up.
    BMC Cancer. 2018;18:935.
    PubMed     Text format     Abstract available


  61. LOPEZ-PINEDA A, Rodriguez-Moran MF, Alvarez-Aguilar C, Fuentes Valle SM, et al
    Data mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes.
    BMC Cancer. 2018;18:933.
    PubMed     Text format     Abstract available


  62. PELIZZARI G, Arpino G, Biganzoli L, Cinieri S, et al
    An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.
    BMC Cancer. 2018;18:932.
    PubMed     Text format     Abstract available


  63. HOYER J, Vasileiou G, Uebe S, Wunderle M, et al
    Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    BMC Cancer. 2018;18:926.
    PubMed     Text format     Abstract available


  64. WANG RX, Chen S, Huang L, Shao ZM, et al
    Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
    BMC Cancer. 2018;18:909.
    PubMed     Text format     Abstract available


  65. JOUALI F, Marchoudi N, Talbi S, Bilal B, et al
    Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
    BMC Cancer. 2018;18:900.
    PubMed     Text format     Abstract available


  66. ELWOOD JM, Tawfiq E, TinTin S, Marshall RJ, et al
    Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index.
    BMC Cancer. 2018;18:897.
    PubMed     Text format     Abstract available


  67. XIONG Z, Deng G, Wang J, Li X, et al
    Could local surgery improve survival in de novo stage IV breast cancer?
    BMC Cancer. 2018;18:885.
    PubMed     Text format     Abstract available


  68. VENTURELLI E, Orenti A, Fabricio ASC, Garrone G, et al
    Correction to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
    BMC Cancer. 2018;18:876.
    PubMed     Text format     Abstract available


  69. SCHLIEMANN D, Donnelly M, Dahlui M, Loh SY, et al
    The 'Be Cancer Alert Campaign': protocol to evaluate a mass media campaign to raise awareness about breast and colorectal cancer in Malaysia.
    BMC Cancer. 2018;18:881.
    PubMed     Text format     Abstract available


  70. SOBOTA A, Ozakinci G
    Determinants of fertility issues experienced by young women diagnosed with breast or gynaecological cancer - a quantitative, cross-cultural study.
    BMC Cancer. 2018;18:874.
    PubMed     Text format     Abstract available


  71. KALINKOVA L, Zmetakova I, Smolkova B, Minarik G, et al
    Decreased methylation in the SNAI2 and ADAM23 genes associated with de-differentiation and haematogenous dissemination in breast cancers.
    BMC Cancer. 2018;18:875.
    PubMed     Text format     Abstract available


  72. FAJKA-BOJA R, Marton A, Toth A, Blazso P, et al
    Increased insulin-like growth factor 1 production by polyploid adipose stem cells promotes growth of breast cancer cells.
    BMC Cancer. 2018;18:872.
    PubMed     Text format     Abstract available


  73. KIRKHAM AA, Paterson DI, Prado CM, Mackey JM, et al
    Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    BMC Cancer. 2018;18:864.
    PubMed     Text format     Abstract available


  74. DUIVON M, Perrier J, Joly F, Licaj I, et al
    Impact of breast cancer on prospective memory functioning assessed by virtual reality and influence of sleep quality and hormonal therapy: PROSOM-K study.
    BMC Cancer. 2018;18:866.
    PubMed     Text format     Abstract available


  75. NIAZI MKK, Senaras C, Pennell M, Arole V, et al
    Relationship between the Ki67 index and its area based approximation in breast cancer.
    BMC Cancer. 2018;18:867.
    PubMed     Text format     Abstract available


  76. BROEDERS MJM, Allgood P, Duffy SW, Hofvind S, et al
    The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review.
    BMC Cancer. 2018;18:860.
    PubMed     Text format     Abstract available


    August 2018
  77. HEIL J, Sinn P, Richter H, Pfob A, et al
    RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
    BMC Cancer. 2018;18:851.
    PubMed     Text format     Abstract available


  78. HULTSCH S, Kankainen M, Paavolainen L, Kovanen RM, et al
    Association of tamoxifen resistance and lipid reprogramming in breast cancer.
    BMC Cancer. 2018;18:850.
    PubMed     Text format     Abstract available


  79. FUMET JD, Wickre M, Jacquot JP, Bizollon MH, et al
    Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer.
    BMC Cancer. 2018;18:839.
    PubMed     Text format     Abstract available


  80. FISH EJ, Irizarry KJ, DeInnocentes P, Ellis CJ, et al
    Malignant canine mammary epithelial cells shed exosomes containing differentially expressed microRNA that regulate oncogenic networks.
    BMC Cancer. 2018;18:832.
    PubMed     Text format     Abstract available


  81. MENG M, Xue H, Lei J, Wang Q, et al
    A novel approach to monitoring the efficacy of anti-tumor treatments in animal models: combining functional MRI and texture analysis.
    BMC Cancer. 2018;18:833.
    PubMed     Text format     Abstract available


  82. VAN BASTELAAR J, Granzier R, van Roozendaal LM, Beets G, et al
    A multi-center, double blind randomized controlled trial evaluating flap fixation after mastectomy using sutures or tissue glue versus conventional closure: protocol for the Seroma reduction After Mastectomy (SAM) trial.
    BMC Cancer. 2018;18:830.
    PubMed     Text format     Abstract available


  83. MENG LL, Wang JL, Xu SP, Zu LD, et al
    Low serum gastrin associated with ER(+) breast cancer development via inactivation of CCKBR/ERK/P65 signaling.
    BMC Cancer. 2018;18:824.
    PubMed     Text format     Abstract available


  84. RICHTER-EHRENSTEIN C, Maak K, Roger S, Ehrenstein T, et al
    Lesions of "uncertain malignant potential" in the breast (B3) identified with mammography screening.
    BMC Cancer. 2018;18:829.
    PubMed     Text format     Abstract available


  85. WANG B, Li D, Rodriguez-Juarez R, Farfus A, et al
    A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
    BMC Cancer. 2018;18:817.
    PubMed     Text format     Abstract available


  86. DENARD B, Jiang S, Peng Y, Ye J, et al
    CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
    BMC Cancer. 2018;18:813.
    PubMed     Text format     Abstract available


  87. AIDERUS A, Black MA, Dunbier AK
    Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers.
    BMC Cancer. 2018;18:805.
    PubMed     Text format     Abstract available


  88. AXELSSON U, Ryden L, Johnsson P, Eden P, et al
    A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study.
    BMC Cancer. 2018;18:789.
    PubMed     Text format     Abstract available


  89. BAEYENS-FERNANDEZ JA, Molina-Portillo E, Pollan M, Rodriguez-Barranco M, et al
    Trends in incidence, mortality and survival in women with breast cancer from 1985 to 2012 in Granada, Spain: a population-based study.
    BMC Cancer. 2018;18:781.
    PubMed     Text format     Abstract available


    July 2018
  90. VIALA M, Chiba A, Thezenas S, Delmond L, et al
    Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study.
    BMC Cancer. 2018;18:770.
    PubMed     Text format     Abstract available


  91. BEELEN K, Opdam M, Severson T, Koornstra R, et al
    Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.
    BMC Cancer. 2018;18:761.
    PubMed     Text format     Abstract available


  92. LEE M, Tayyari F, Pinnaduwage D, Bayani J, et al
    Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
    BMC Cancer. 2018;18:750.
    PubMed     Text format     Abstract available


  93. GIBBONS JA, Kanwar JR, Kanwar RK
    Correction to: Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer.
    BMC Cancer. 2018;18:749.
    PubMed     Text format     Abstract available


  94. RETHORST CD, Hamann HA, Carmody TJ, Sharp KJ, et al
    The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors.
    BMC Cancer. 2018;18:744.
    PubMed     Text format     Abstract available


  95. VASMATZIS G, Wang X, Smadbeck JB, Murphy SJ, et al
    Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2(+) breast cancer samples.
    BMC Cancer. 2018;18:738.
    PubMed     Text format     Abstract available


  96. LAMBERT LK, Balneaves LG, Howard AF, Chia SK, et al
    Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    BMC Cancer. 2018;18:732.
    PubMed     Text format     Abstract available


  97. NUSHTAEVA AA, Stepanov GA, Semenov DV, Juravlev ES, et al
    Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents.
    BMC Cancer. 2018;18:728.
    PubMed     Text format     Abstract available


  98. HE Y, Tan EH, Wong ALA, Tan CC, et al
    Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: study protocol of a randomised controlled trial to evaluate the effect of short message service (SMS) reminder.
    BMC Cancer. 2018;18:727.
    PubMed     Text format     Abstract available


  99. YOON YN, Choe MH, Jung KY, Hwang SG, et al
    MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells.
    BMC Cancer. 2018;18:716.
    PubMed     Text format     Abstract available


  100. SLAOUI M, Zoure AA, Mouh FZ, Bensouda Y, et al
    Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).
    BMC Cancer. 2018;18:713.
    PubMed     Text format     Abstract available


  101. REAL SAS, Parveen F, Rehman AU, Khan MA, et al
    Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients.
    BMC Cancer. 2018;18:711.
    PubMed     Text format     Abstract available


  102. RANGEL N, Fortunati N, Osella-Abate S, Annaratone L, et al
    FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.
    BMC Cancer. 2018;18:703.
    PubMed     Text format     Abstract available


    June 2018
  103. ZOPPINO FCM, Guerrero-Gimenez ME, Castro GN, Ciocca DR, et al
    Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer.
    BMC Cancer. 2018;18:700.
    PubMed     Text format     Abstract available


  104. HAYASHIDA T, Jinno H, Mori K, Sato H, et al
    Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
    BMC Cancer. 2018;18:701.
    PubMed     Text format     Abstract available


  105. VAN GELDERMALSEN M, Quek LE, Turner N, Freidman N, et al
    Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways.
    BMC Cancer. 2018;18:689.
    PubMed     Text format     Abstract available


  106. EHLERS DK, Fanning J, Salerno EA, Aguinaga S, et al
    Replacing sedentary time with physical activity or sleep: effects on cancer-related cognitive impairment in breast cancer survivors.
    BMC Cancer. 2018;18:685.
    PubMed     Text format     Abstract available


  107. GREGOIRE C, Nicolas H, Bragard I, Delevallez F, et al
    Efficacy of a hypnosis-based intervention to improve well-being during cancer: a comparison between prostate and breast cancer patients.
    BMC Cancer. 2018;18:677.
    PubMed     Text format     Abstract available


  108. INOUE K, Ninomiya J, Saito T, Kimizuka K, et al
    Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 3
    BMC Cancer. 2018;18:671.
    PubMed     Text format     Abstract available


  109. LI Y, Du Y, Sun T, Xue H, et al
    PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.
    BMC Cancer. 2018;18:669.
    PubMed     Text format     Abstract available


  110. LI R, Xiao C, Liu H, Huang Y, et al
    Effects of local anesthetics on breast cancer cell viability and migration.
    BMC Cancer. 2018;18:666.
    PubMed     Text format     Abstract available


  111. XU H, Xu Y, Ouyang T, Li J, et al
    Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients.
    BMC Cancer. 2018;18:662.
    PubMed     Text format     Abstract available


  112. LOFTEROD T, Mortensen ES, Nalwoga H, Wilsgaard T, et al
    Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.
    BMC Cancer. 2018;18:654.
    PubMed     Text format     Abstract available


  113. VENTURELLI E, Orenti A, Fabricio ASC, Garrone G, et al
    Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
    BMC Cancer. 2018;18:651.
    PubMed     Text format     Abstract available


  114. DUSENGIMANA JMV, Hategekimana V, Borg R, Hedt-Gauthier B, et al
    Pregnancy-associated breast cancer in rural Rwanda: the experience of the Butaro Cancer Center of Excellence.
    BMC Cancer. 2018;18:634.
    PubMed     Text format     Abstract available


    May 2018
  115. NATTENMULLER CJ, Kriegsmann M, Sookthai D, Fortner RT, et al
    Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study.
    BMC Cancer. 2018;18:616.
    PubMed     Text format     Abstract available


  116. WHITNEY J, Corredor G, Janowczyk A, Ganesan S, et al
    Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
    BMC Cancer. 2018;18:610.
    PubMed     Text format     Abstract available


  117. MADHU KRISHNA B, Chaudhary S, Mishra DR, Naik SK, et al
    Estrogen receptor alpha dependent regulation of estrogen related receptor beta and its role in cell cycle in breast cancer.
    BMC Cancer. 2018;18:607.
    PubMed     Text format     Abstract available


  118. HOUSE CD, Grajales V, Ozaki M, Jordan E, et al
    IKappaKappaepsilon cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.
    BMC Cancer. 2018;18:595.
    PubMed     Text format     Abstract available


  119. MUDDUWA L, Peiris H, Gunasekara S, Abeysiriwardhana D, et al
    KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy.
    BMC Cancer. 2018;18:589.
    PubMed     Text format     Abstract available


  120. FORTE L, Turdo F, Ghirelli C, Aiello P, et al
    The PDGFRbeta/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
    BMC Cancer. 2018;18:586.
    PubMed     Text format     Abstract available


  121. BUCZEK E, Denslow A, Mateuszuk L, Proniewski B, et al
    Alterations in NO- and PGI2- dependent function in aorta in the orthotopic murine model of metastatic 4T1 breast cancer: relationship with pulmonary endothelial dysfunction and systemic inflammation.
    BMC Cancer. 2018;18:582.
    PubMed     Text format     Abstract available


  122. PARASHAR S, Cheishvili D, Mahmood N, Arakelian A, et al
    DNA methylation signatures of breast cancer in peripheral T-cells.
    BMC Cancer. 2018;18:574.
    PubMed     Text format     Abstract available


  123. BATES JP, Derakhshandeh R, Jones L, Webb TJ, et al
    Mechanisms of immune evasion in breast cancer.
    BMC Cancer. 2018;18:556.
    PubMed     Text format     Abstract available


  124. BANYS-PALUCHOWSKI M, Fehm T, Janni W, Aktas B, et al
    Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
    BMC Cancer. 2018;18:541.
    PubMed     Text format     Abstract available


  125. SHULDINER J, Liu Y, Lofters A
    Incidence of breast and colorectal cancer among immigrants in Ontario, Canada: a retrospective cohort study from 2004-2014.
    BMC Cancer. 2018;18:537.
    PubMed     Text format     Abstract available


  126. DOUGAN MM, Li Y, Chu LW, Haile RW, et al
    Metabolomic profiles in breast cancer:a pilot case-control study in the breast cancer family registry.
    BMC Cancer. 2018;18:532.
    PubMed     Text format     Abstract available


  127. NAIK A, Al-Yahyaee A, Abdullah N, Sam JE, et al
    Neuropilin-1 promotes the oncogenic Tenascin-C/integrin beta3 pathway and modulates chemoresistance in breast cancer cells.
    BMC Cancer. 2018;18:533.
    PubMed     Text format     Abstract available


  128. PENAULT-LLORCA F, Filleron T, Asselain B, Baehner FL, et al
    The 21-gene Recurrence Score(R) assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 tria
    BMC Cancer. 2018;18:526.
    PubMed     Text format     Abstract available


  129. LI W, Xu L, Che X, Li H, et al
    C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
    BMC Cancer. 2018;18:507.
    PubMed     Text format     Abstract available


  130. DI GIROLAMO C, Walters S, Benitez Majano S, Rachet B, et al
    Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013.
    BMC Cancer. 2018;18:492.
    PubMed     Text format     Abstract available


    April 2018
  131. HUANG S, Murphy L, Xu W
    Genes and functions from breast cancer signatures.
    BMC Cancer. 2018;18:473.
    PubMed     Text format     Abstract available


  132. FERNANDO A, Jayarajah U, Prabashani S, Fernando EA, et al
    Incidence trends and patterns of breast cancer in Sri Lanka: an analysis of the national cancer database.
    BMC Cancer. 2018;18:482.
    PubMed     Text format     Abstract available


  133. BAUERSFELD SP, Kessler CS, Wischnewsky M, Jaensch A, et al
    The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study.
    BMC Cancer. 2018;18:476.
    PubMed     Text format     Abstract available


  134. DOGAN A, Kern P, Schultheis B, Hausler G, et al
    Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.
    BMC Cancer. 2018;18:463.
    PubMed     Text format     Abstract available


  135. CATSMAN CJLM, Beek MA, Voogd AC, Mulder PGH, et al
    The COSMAM TRIAL a prospective cohort study of quality of life and cosmetic outcome in patients undergoing breast conserving surgery.
    BMC Cancer. 2018;18:456.
    PubMed     Text format     Abstract available


  136. LIUTKAUSKIENE S, Grizas S, Jureniene K, Suipyte J, et al
    Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes.
    BMC Cancer. 2018;18:453.
    PubMed     Text format     Abstract available


  137. PODRALSKA M, Ziolkowska-Suchanek I, Zurawek M, Dzikiewicz-Krawczyk A, et al
    Genetic variants in ATM, H2AFX and MRE11 genes and susceptibility to breast cancer in the polish population.
    BMC Cancer. 2018;18:452.
    PubMed     Text format     Abstract available


  138. JIN J, Gao Y, Zhang J, Wang L, et al
    Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.
    BMC Cancer. 2018;18:446.
    PubMed     Text format     Abstract available


  139. SEMMLINGER A, von Schoenfeldt V, Wolf V, Meuter A, et al
    EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
    BMC Cancer. 2018;18:431.
    PubMed     Text format     Abstract available


  140. XIAO B, Chen L, Ke Y, Hang J, et al
    Identification of methylation sites and signature genes with prognostic value for luminal breast cancer.
    BMC Cancer. 2018;18:405.
    PubMed     Text format     Abstract available


  141. DEFOSSEZ G, Quillet A, Ingrand P
    Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers.
    BMC Cancer. 2018;18:393.
    PubMed     Text format     Abstract available


  142. HILLER L, Dunn JA, Loi S, Vallier AL, et al
    Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
    BMC Cancer. 2018;18:391.
    PubMed     Text format     Abstract available


  143. VAN DER WAAL D, Verbeek ALM, Broeders MJM
    Breast density and breast cancer-specific survival by detection mode.
    BMC Cancer. 2018;18:386.
    PubMed     Text format     Abstract available


  144. BALEKOUZOU A, Yin P, Bekolo CE, Pamatika CM, et al
    Histo-epidemiological profile of breast cancers among women in the Central African Republic: about 174 cases.
    BMC Cancer. 2018;18:387.
    PubMed     Text format     Abstract available


  145. PHI XA, Tagliafico A, Houssami N, Greuter MJW, et al
    Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts - a systematic review and meta-analysis.
    BMC Cancer. 2018;18:380.
    PubMed     Text format     Abstract available


  146. HUNG CH, Chen FM, Lin YC, Tsai ML, et al
    Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer.
    BMC Cancer. 2018;18:366.
    PubMed     Text format     Abstract available


  147. LIU Y, Du Y, Hu X, Zhao L, et al
    Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer.
    BMC Cancer. 2018;18:367.
    PubMed     Text format     Abstract available


    March 2018
  148. AN X, Xu F, Luo R, Zheng Q, et al
    The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
    BMC Cancer. 2018;18:331.
    PubMed     Text format     Abstract available


  149. CHEN J, Zhu Y, Zhang W, Peng X, et al
    Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells.
    BMC Cancer. 2018;18:342.
    PubMed     Text format     Abstract available


  150. DITTUS KL, Harvey JR, Bunn JY, Kokinda ND, et al
    Impact of a behaviorally-based weight loss intervention on parameters of insulin resistance in breast cancer survivors.
    BMC Cancer. 2018;18:351.
    PubMed     Text format     Abstract available


  151. BRONTE G, Rocca A, Ravaioli S, Puccetti M, et al
    Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    BMC Cancer. 2018;18:348.
    PubMed     Text format     Abstract available


  152. XU Y, Yang X, Wang T, Yang L, et al
    Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-gamma-linolenic acid peroxidation dependent mechanism.
    BMC Cancer. 2018;18:330.
    PubMed     Text format     Abstract available


  153. SALIMI M, Wang R, Yao X, Li X, et al
    Activated innate lymphoid cell populations accumulate in human tumour tissues.
    BMC Cancer. 2018;18:341.
    PubMed     Text format     Abstract available


  154. MARMARA D, Marmara V, Hubbard G
    A national cross-sectional study of adherence to timely mammography use in Malta.
    BMC Cancer. 2018;18:346.
    PubMed     Text format     Abstract available


  155. AHN SG, Cha YJ, Bae SJ, Yoon C, et al
    Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
    BMC Cancer. 2018;18:320.
    PubMed     Text format     Abstract available


  156. WANG YA, Jian JW, Hung CF, Peng HP, et al
    Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    BMC Cancer. 2018;18:315.
    PubMed     Text format     Abstract available


  157. MOODLEY J, Cairncross L, Naiker T, Constant D, et al
    From symptom discovery to treatment - women's pathways to breast cancer care: a cross-sectional study.
    BMC Cancer. 2018;18:312.
    PubMed     Text format     Abstract available


  158. ZHANG JJ, Shu H, Hu SS, Yu Y, et al
    Relationship between time elapsed since completion of radiotherapy and quality of life of patients with breast cancer.
    BMC Cancer. 2018;18:305.
    PubMed     Text format     Abstract available


  159. MENSAH KB, Oosthuizen F, Bonsu AB
    Cancer awareness among community pharmacist: a systematic review.
    BMC Cancer. 2018;18:299.
    PubMed     Text format     Abstract available


  160. MULLER V, Clemens M, Jassem J, Al-Sakaff N, et al
    Long-term trastuzumab (Herceptin(R)) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
    BMC Cancer. 2018;18:295.
    PubMed     Text format     Abstract available


  161. HARDI H, Melki R, Boughaleb Z, El Harroudi T, et al
    Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
    BMC Cancer. 2018;18:292.
    PubMed     Text format     Abstract available


  162. MCANENA PF, McGuire A, Ramli A, Curran C, et al
    Correction to: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.
    BMC Cancer. 2018;18:282.
    PubMed     Text format     Abstract available


  163. DAVID D, Surendran A, Thulaseedharan JV, Nair AS, et al
    Regulation of CNKSR2 protein stability by the HECT E3 ubiquitin ligase Smurf2, and its role in breast cancer progression.
    BMC Cancer. 2018;18:284.
    PubMed     Text format     Abstract available


  164. DIERSSEN-SOTOS T, Palazuelos-Calderon C, Jimenez-Moleon JJ, Aragones N, et al
    Reproductive risk factors in breast cancer and genetic hormonal pathways: a gene-environment interaction in the MCC-Spain project.
    BMC Cancer. 2018;18:280.
    PubMed     Text format     Abstract available


  165. SONG Q, Chen Q, Wang Q, Yang L, et al
    ATF-3/miR-590/GOLPH3 signaling pathway regulates proliferation of breast cancer.
    BMC Cancer. 2018;18:255.
    PubMed     Text format     Abstract available


  166. NAAB TJ, Gautam A, Ricks-Santi L, Esnakula AK, et al
    MYC amplification in subtypes of breast cancers in African American women.
    BMC Cancer. 2018;18:274.
    PubMed     Text format     Abstract available


  167. YANG L, Wang J, Cheng J, Wang Y, et al
    Quality assurance target for community-based breast cancer screening in China: a model simulation.
    BMC Cancer. 2018;18:261.
    PubMed     Text format     Abstract available


  168. VONDELING GT, Menezes GL, Dvortsin EP, Jansman FGA, et al
    Burden of early, advanced and metastatic breast cancer in The Netherlands.
    BMC Cancer. 2018;18:262.
    PubMed     Text format     Abstract available


  169. ENGEL C, Rhiem K, Hahnen E, Loibl S, et al
    Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    BMC Cancer. 2018;18:265.
    PubMed     Text format     Abstract available


  170. ANWAR SL, Tampubolon G, Van Hemelrijck M, Hutajulu SH, et al
    Determinants of cancer screening awareness and participation among Indonesian women.
    BMC Cancer. 2018;18:208.
    PubMed     Text format     Abstract available


  171. SANKATSING VDV, Fracheboud J, de Munck L, Broeders MJM, et al
    Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening.
    BMC Cancer. 2018;18:256.
    PubMed     Text format     Abstract available


    February 2018
  172. ISFOSS BL, Holmqvist B, Sand E, Forsell J, et al
    Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer - an observational study.
    BMC Cancer. 2018;18:230.
    PubMed     Text format     Abstract available


  173. SOOTICHOTE R, Thuwajit P, Singsuksawat E, Warnnissorn M, et al
    Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
    BMC Cancer. 2018;18:231.
    PubMed     Text format     Abstract available


  174. GAVA F, Rigal L, Mondesert O, Pesce E, et al
    Gap junctions contribute to anchorage-independent clustering of breast cancer cells.
    BMC Cancer. 2018;18:221.
    PubMed     Text format     Abstract available


  175. JAASKELAINEN A, Soini Y, Jukkola-Vuorinen A, Auvinen P, et al
    High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.
    BMC Cancer. 2018;18:223.
    PubMed     Text format     Abstract available


  176. BRONSVELD HK, De Bruin ML, Wesseling J, Sanders J, et al
    The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.
    BMC Cancer. 2018;18:224.
    PubMed     Text format     Abstract available


  177. HOU MF, Chen PM, Chu PY
    LGR5 overexpression confers poor relapse-free survival in breast cancer patients.
    BMC Cancer. 2018;18:219.
    PubMed     Text format     Abstract available


  178. MCANENA PF, Brown JA, Ramli A, Curran C, et al
    Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.
    BMC Cancer. 2018;18:203.
    PubMed     Text format     Abstract available


  179. HUEBNER H, Fasching PA, Gumbrecht W, Jud S, et al
    Filtration based assessment of CTCs and CellSearch(R) based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    BMC Cancer. 2018;18:204.
    PubMed     Text format     Abstract available


  180. WESTVIK AS, Weedon-Fekjaer H, Maehlen J, Liestol K, et al
    Evaluating different breast tumor progression models using screening data.
    BMC Cancer. 2018;18:209.
    PubMed     Text format     Abstract available


  181. SIRISENA ND, Adeyemo A, Kuruppu AI, Neththikumara N, et al
    Genetic determinants of sporadic breast cancer in Sri Lankan women.
    BMC Cancer. 2018;18:180.
    PubMed     Text format     Abstract available


  182. NOJIMA M, Iwasaki M, Kasuga Y, Yokoyama S, et al
    Correlation between global methylation level of peripheral blood leukocytes and serum C reactive protein level modified by MTHFR polymorphism: a cross-sectional study.
    BMC Cancer. 2018;18:184.
    PubMed     Text format     Abstract available


  183. KODAIRA M, Yonemori K, Shimoi T, Yoshida A, et al
    Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    BMC Cancer. 2018;18:176.
    PubMed     Text format     Abstract available


  184. IBRAHIM M, Yadav S, Ogunleye F, Zakalik D, et al
    Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    BMC Cancer. 2018;18:179.
    PubMed     Text format     Abstract available


  185. KJALLQUIST U, Erlandsson R, Tobin NP, Alkodsi A, et al
    Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs).
    BMC Cancer. 2018;18:174.
    PubMed     Text format     Abstract available


  186. AL DOSSARY R, Alkharsah KR, Kussaibi H
    Prevalence of Mouse Mammary Tumor Virus (MMTV)-like sequences in human breast cancer tissues and adjacent normal breast tissues in Saudi Arabia.
    BMC Cancer. 2018;18:170.
    PubMed     Text format     Abstract available


  187. LAFOURCADE A, His M, Baglietto L, Boutron-Ruault MC, et al
    Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort.
    BMC Cancer. 2018;18:171.
    PubMed     Text format     Abstract available


  188. NGUYEN-DUMONT T, Teo ZL, Hammet F, Roberge A, et al
    Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?
    BMC Cancer. 2018;18:165.
    PubMed     Text format     Abstract available


  189. CORTET M, Bertaut A, Molinie F, Bara S, et al
    Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries.
    BMC Cancer. 2018;18:161.
    PubMed     Text format     Abstract available


  190. LAM WWT, Kwong A, Suen D, Tsang J, et al
    Factors predicting patient satisfaction in women with advanced breast cancer: a prospective study.
    BMC Cancer. 2018;18:162.
    PubMed     Text format     Abstract available


  191. LIM JA, Oh CS, Yoon TG, Lee JY, et al
    The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis.
    BMC Cancer. 2018;18:159.
    PubMed     Text format     Abstract available


  192. ABDEL-RAZEQ H, Al-Omari A, Zahran F, Arun B, et al
    Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan.
    BMC Cancer. 2018;18:152.
    PubMed     Text format     Abstract available


  193. PENSABENE M, Stanzione B, Cerillo I, Ciancia G, et al
    It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature.
    BMC Cancer. 2018;18:146.
    PubMed     Text format     Abstract available


  194. ALUNNI-FABBRONI M, Majunke L, Trapp EK, Tzschaschel M, et al
    Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
    BMC Cancer. 2018;18:141.
    PubMed     Text format     Abstract available


  195. TRAORE BM, El Fakir S, Charaka H, Benaicha N, et al
    Evolution of quality of life in patients with breast cancer during the first year of follow-up in Morocco.
    BMC Cancer. 2018;18:109.
    PubMed     Text format     Abstract available


  196. NOVAK J, Besic N, Dzodic R, Gazic B, et al
    Pre-operative and intra-operative detection of axillary lymph node metastases in 108 patients with invasive lobular breast cancer undergoing mastectomy.
    BMC Cancer. 2018;18:137.
    PubMed     Text format     Abstract available


  197. BEGUINOT M, Dauplat MM, Kwiatkowski F, Lebouedec G, et al
    Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
    BMC Cancer. 2018;18:129.
    PubMed     Text format     Abstract available


  198. KAEWKANGSADAN V, Verma C, Eremin JM, Cowley G, et al
    Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumo
    BMC Cancer. 2018;18:123.
    PubMed     Text format     Abstract available


    January 2018
  199. EVANS RL, Pottala JV, Nagata S, Egland KA, et al
    Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.
    BMC Cancer. 2018;18:119.
    PubMed     Text format     Abstract available


  200. HSIEH E, Wang Q, Zhang R, Niu X, et al
    Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gaps.
    BMC Cancer. 2018;18:104.
    PubMed     Text format     Abstract available


  201. FRERES P, Bouznad N, Servais L, Josse C, et al
    Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients.
    BMC Cancer. 2018;18:102.
    PubMed     Text format     Abstract available


  202. RICCIARDI GRR, Russo A, Franchina T, Schifano S, et al
    Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    BMC Cancer. 2018;18:97.
    PubMed     Text format     Abstract available


  203. HAQUE I, Ghosh A, Acup S, Banerjee S, et al
    Leptin-induced ER-alpha-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway.
    BMC Cancer. 2018;18:99.
    PubMed     Text format     Abstract available


  204. DE LIGT KM, Witteveen A, Siesling S, Steuten LMG, et al
    Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study.
    BMC Cancer. 2018;18:96.
    PubMed     Text format     Abstract available


  205. PARK VY, Kim EK, Kim MJ, Moon HJ, et al
    Breast magnetic resonance imaging for surveillance of women with a personal history of breast cancer: outcomes stratified by interval between definitive surgery and surveillance MR imaging.
    BMC Cancer. 2018;18:91.
    PubMed     Text format     Abstract available


  206. PARK JS, Lee ST, Nam EJ, Han JW, et al
    Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
    BMC Cancer. 2018;18:83.
    PubMed     Text format     Abstract available


  207. ELWOOD JM, Tin Tin S, Kuper-Hommel M, Lawrenson R, et al
    Obesity and breast cancer outcomes in chemotherapy patients in New Zealand - a population-based cohort study.
    BMC Cancer. 2018;18:76.
    PubMed     Text format     Abstract available


  208. BERNAL-ESTEVEZ DA, Garcia O, Sanchez R, Parra-Lopez CA, et al
    Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy.
    BMC Cancer. 2018;18:77.
    PubMed     Text format     Abstract available


  209. YU SJ, Yang L, Hong Q, Kuang XY, et al
    MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer.
    BMC Cancer. 2018;18:74.
    PubMed     Text format     Abstract available


  210. GARCIA-GUTIERREZ S, Orive M, Sarasqueta C, Legarreta MJ, et al
    Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study.
    BMC Cancer. 2018;18:54.
    PubMed     Text format     Abstract available


  211. DALL P, Koch T, Gohler T, Selbach J, et al
    Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study.
    BMC Cancer. 2018;18:51.
    PubMed     Text format     Abstract available


  212. TIN TIN S, Elwood JM, Brown C, Sarfati D, et al
    Ethnic disparities in breast cancer survival in New Zealand: which factors contribute?
    BMC Cancer. 2018;18:58.
    PubMed     Text format     Abstract available


  213. URRU SAM, Gallus S, Bosetti C, Moi T, et al
    Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    BMC Cancer. 2018;18:56.
    PubMed     Text format     Abstract available


  214. KUMAR D, Haldar S, Gorain M, Kumar S, et al
    Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway.
    BMC Cancer. 2018;18:52.
    PubMed     Text format     Abstract available


  215. LOVITT CJ, Shelper TB, Avery VM
    Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins.
    BMC Cancer. 2018;18:41.
    PubMed     Text format     Abstract available


  216. PARK E, Yoon J, Choi EK, Kim IR, et al
    A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors.
    BMC Cancer. 2018;18:45.
    PubMed     Text format     Abstract available


  217. LOUHICHI T, Saad H, Dhiab MB, Ziadi S, et al
    Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype.
    BMC Cancer. 2018;18:49.
    PubMed     Text format     Abstract available


  218. HERNANDEZ RK, Wade SW, Reich A, Pirolli M, et al
    Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
    BMC Cancer. 2018;18:44.
    PubMed     Text format     Abstract available


  219. NZEANGUNG BA, Biwole ME, Kadia BM, Bechem NN, et al
    Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: a 16-year retrospective review at the Douala general hospital, Cameroon.
    BMC Cancer. 2018;18:32.
    PubMed     Text format     Abstract available


  220. NARRANDES S, Huang S, Murphy L, Xu W, et al
    The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
    BMC Cancer. 2018;18:22.
    PubMed     Text format     Abstract available


  221. ZHOU K, He X, Huo L, An J, et al
    Development of the body image self-rating questionnaire for breast cancer (BISQ-BC) for Chinese mainland patients.
    BMC Cancer. 2018;18:19.
    PubMed     Text format     Abstract available


  222. PATRICIO M, Pereira J, Crisostomo J, Matafome P, et al
    Using Resistin, glucose, age and BMI to predict the presence of breast cancer.
    BMC Cancer. 2018;18:29.
    PubMed     Text format     Abstract available


  223. LI M, Li A, Zhou S, Xu Y, et al
    Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    BMC Cancer. 2018;18:4.
    PubMed     Text format     Abstract available


    December 2017
  224. LYNGE E, Bak M, von Euler-Chelpin M, Kroman N, et al
    Outcome of breast cancer screening in Denmark.
    BMC Cancer. 2017;17:897.
    PubMed     Text format     Abstract available


  225. HUANG LH, Chung HY, Su HM
    Docosahexaenoic acid reduces sterol regulatory element binding protein-1 and fatty acid synthase expression and inhibits cell proliferation by inhibiting pAkt signaling in a human breast cancer MCF-7 cell line.
    BMC Cancer. 2017;17:890.
    PubMed     Text format     Abstract available


  226. ASANO Y, Kashiwagi S, Goto W, Takada K, et al
    Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    BMC Cancer. 2017;17:888.
    PubMed     Text format     Abstract available


  227. MERCOGLIANO MF, Inurrigarro G, De Martino M, Venturutti L, et al
    Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
    BMC Cancer. 2017;17:895.
    PubMed     Text format     Abstract available


  228. LIU LN, Lin YC, Miaskowski C, Chen SC, et al
    Association between changes in body fat and disease progression after breast cancer surgery is moderated by menopausal status.
    BMC Cancer. 2017;17:863.
    PubMed     Text format     Abstract available


  229. KRISHNAN K, Baglietto L, Stone J, McLean C, et al
    Mammographic density and risk of breast cancer by tumor characteristics: a case-control study.
    BMC Cancer. 2017;17:859.
    PubMed     Text format     Abstract available


  230. KUMARI K, Keshari S, Sengupta D, Sabat SC, et al
    Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.
    BMC Cancer. 2017;17:858.
    PubMed     Text format     Abstract available


  231. WU Y, Zhang N, Yang Q
    The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis.
    BMC Cancer. 2017;17:839.
    PubMed     Text format     Abstract available


  232. GAO D, Cazares LH, Fish EN
    CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis.
    BMC Cancer. 2017;17:834.
    PubMed     Text format     Abstract available


  233. BAXTER GD, Liu L, Petrich S, Gisselman AS, et al
    Low level laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review.
    BMC Cancer. 2017;17:833.
    PubMed     Text format     Abstract available


  234. PHAM TND, Perez White BE, Zhao H, Mortazavi F, et al
    Protein kinase C alpha enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin.
    BMC Cancer. 2017;17:832.
    PubMed     Text format     Abstract available


  235. KO H, Shin J, Lee JE, Nam SJ, et al
    Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women.
    BMC Cancer. 2017;17:821.
    PubMed     Text format     Abstract available


  236. OCHNIK AM, Baxter RC
    Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer.
    BMC Cancer. 2017;17:820.
    PubMed     Text format     Abstract available


  237. HE D, Fang Y, Gunter MJ, Xu D, et al
    Incidence of breast cancer in Chinese women exposed to the 1959-1961 great Chinese famine.
    BMC Cancer. 2017;17:824.
    PubMed     Text format     Abstract available


  238. IIZUMI S, Shimoi T, Tsushita N, Bun S, et al
    Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
    BMC Cancer. 2017;17:819.
    PubMed     Text format     Abstract available


  239. THOMAS ET, Del Mar C, Glasziou P, Wright G, et al
    Prevalence of incidental breast cancer and precursor lesions in autopsy studies: a systematic review and meta-analysis.
    BMC Cancer. 2017;17:808.
    PubMed     Text format     Abstract available


  240. SENGAL AT, Haj-Mukhtar NS, Elhaj AM, Bedri S, et al
    Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
    BMC Cancer. 2017;17:804.
    PubMed     Text format     Abstract available


    November 2017
  241. KARTHIK GM, Rantalainen M, Stalhammar G, Lovrot J, et al
    Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling.
    BMC Cancer. 2017;17:802.
    PubMed     Text format     Abstract available


  242. QATTAN A, Intabli H, Alkhayal W, Eltabache C, et al
    Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
    BMC Cancer. 2017;17:799.
    PubMed     Text format     Abstract available


  243. GIORDANO L, Gallo F, Petracci E, Chiorino G, et al
    The ANDROMEDA prospective cohort study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: study protocol.
    BMC Cancer. 2017;17:785.
    PubMed     Text format     Abstract available


  244. TAKESHITA T, Yamamoto Y, Yamamoto-Ibusuki M, Sueta A, et al
    Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
    BMC Cancer. 2017;17:786.
    PubMed     Text format     Abstract available


  245. WONG XY, Chong KJ, van Til JA, Wee HL, et al
    A qualitative study on Singaporean women's views towards breast cancer screening and Single Nucleotide Polymorphisms (SNPs) gene testing to guide personalised screening strategies.
    BMC Cancer. 2017;17:776.
    PubMed     Text format     Abstract available


  246. SHIROIWA T, Fukuda T, Shimozuma K, Mouri M, et al
    Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
    BMC Cancer. 2017;17:773.
    PubMed     Text format     Abstract available


  247. ISAKOVA J, Talaibekova E, Aldasheva N, Vinnikov D, et al
    The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.
    BMC Cancer. 2017;17:758.
    PubMed     Text format     Abstract available


  248. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Van de Vijver MJ, et al
    Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer.
    BMC Cancer. 2017;17:755.
    PubMed     Text format     Abstract available


  249. LI J, Lai Y, Ma J, Liu Y, et al
    miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    BMC Cancer. 2017;17:745.
    PubMed     Text format     Abstract available


  250. KHAN UT, Walker AJ, Baig S, Card TR, et al
    Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis.
    BMC Cancer. 2017;17:747.
    PubMed     Text format     Abstract available


  251. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Text format     Abstract available


  252. MINICHILLO S, Gallelli I, Barbieri E, Cubelli M, et al
    Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.
    BMC Cancer. 2017;17:722.
    PubMed     Text format     Abstract available


  253. QUINTERO M, Adamoski D, Reis LMD, Ascencao CFR, et al
    Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
    BMC Cancer. 2017;17:727.
    PubMed     Text format     Abstract available


  254. GOHR K, Hamacher A, Engelke LH, Kassack MU, et al
    Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    BMC Cancer. 2017;17:711.
    PubMed     Text format     Abstract available


  255. LANZ HL, Saleh A, Kramer B, Cairns J, et al
    Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
    BMC Cancer. 2017;17:709.
    PubMed     Text format     Abstract available


    October 2017
  256. REPO H, Gurvits N, Loyttyniemi E, Nykanen M, et al
    PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.
    BMC Cancer. 2017;17:705.
    PubMed     Text format     Abstract available


  257. D'ALOISIO AA, Nichols HB, Hodgson ME, Deming-Halverson SL, et al
    Validity of self-reported breast cancer characteristics in a nationwide cohort of women with a family history of breast cancer.
    BMC Cancer. 2017;17:692.
    PubMed     Text format     Abstract available


  258. KIM HM, Lee J, Koo JS
    Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
    BMC Cancer. 2017;17:690.
    PubMed     Text format     Abstract available


  259. JAHN B, Rochau U, Kurzthaler C, Hubalek M, et al
    Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.
    BMC Cancer. 2017;17:685.
    PubMed     Text format     Abstract available


  260. LYSZCZARZ B, Nojszewska E
    Productivity losses and public finance burden attributable to breast cancer in Poland, 2010-2014.
    BMC Cancer. 2017;17:676.
    PubMed     Text format     Abstract available


    September 2017
  261. ABHYANKAR N, Hoskins KF, Abern MR, Calip GS, et al
    Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.
    BMC Cancer. 2017;17:659.
    PubMed     Text format     Abstract available


  262. REITHMEIER A, Panizza E, Krumpel M, Orre LM, et al
    Tartrate-resistant acid phosphatase (TRAP/ACP5) promotes metastasis-related properties via TGFbeta2/TbetaR and CD44 in MDA-MB-231 breast cancer cells.
    BMC Cancer. 2017;17:650.
    PubMed     Text format     Abstract available


  263. REYNOLDS KL, Bedard PL, Lee SH, Lin CC, et al
    A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
    BMC Cancer. 2017;17:646.
    PubMed     Text format     Abstract available


  264. HUSSAIN AR, Siraj AK, Ahmed M, Bu R, et al
    XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.
    BMC Cancer. 2017;17:640.
    PubMed     Text format     Abstract available


  265. DEB S, Gorringe KL, Pang JB, Byrne DJ, et al
    BRCA2 carriers with male breast cancer show elevated tumour methylation.
    BMC Cancer. 2017;17:641.
    PubMed     Text format     Abstract available


    May 2017
  266. VOELS B, Wang L, Sens DA, Garrett SH, et al
    The unique C- and N-terminal sequences of Metallothionein isoform 3 mediate growth inhibition and Vectorial active transport in MCF-7 cells.
    BMC Cancer. 2017;17:369.
    PubMed     Text format     Abstract available


  267. DEMOOR-GOLDSCHMIDT C, Drui D, Doutriaux I, Michel G, et al
    A French national breast and thyroid cancer screening programme for survivors of childhood, adolescent and young adult (CAYA) cancers - DeNaCaPST programme.
    BMC Cancer. 2017;17:326.
    PubMed     Text format     Abstract available


  268. BOGAN D, Meile L, El Bastawisy A, Yousef HF, et al
    The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    BMC Cancer. 2017;17:329.
    PubMed     Text format     Abstract available


  269. CHIN-QUEE K, Donahue HJ
    MDA-MET-conditioned-medium augments the chemoattractant-dependent migration of MDA-MET cells towards hFOB-conditioned medium and increases collagenase activity.
    BMC Cancer. 2017;17:324.
    PubMed     Text format     Abstract available


    April 2017
  270. JUNG SY, Sobel EM, Papp JC, Zhang ZF, et al
    Effect of genetic variants and traits related to glucose metabolism and their interaction with obesity on breast and colorectal cancer risk among postmenopausal women.
    BMC Cancer. 2017;17:290.
    PubMed     Text format     Abstract available


    March 2017
  271. BERNTSEN S, Aaronson NK, Buffart L, Borjeson S, et al
    Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.
    BMC Cancer. 2017;17:218.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: